Logo image of VRAX

VIRAX BIOLABS GROUP LTD (VRAX) Stock Fundamental Analysis

NASDAQ:VRAX - Nasdaq - KYG9495L1251 - Common Stock - Currency: USD

1.36  -0.11 (-7.48%)

Premarket: 1.41 +0.05 (+3.68%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to VRAX. VRAX was compared to 108 industry peers in the Health Care Providers & Services industry. The financial health of VRAX is average, but there are quite some concerns on its profitability. VRAX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VRAX has reported negative net income.
In the past year VRAX has reported a negative cash flow from operations.
VRAX had negative earnings in each of the past 5 years.
In the past 5 years VRAX always reported negative operating cash flow.
VRAX Yearly Net Income VS EBIT VS OCF VS FCFVRAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

With a Return On Assets value of -69.69%, VRAX is not doing good in the industry: 90.74% of the companies in the same industry are doing better.
The Return On Equity of VRAX (-76.12%) is worse than 73.15% of its industry peers.
Industry RankSector Rank
ROA -69.69%
ROE -76.12%
ROIC N/A
ROA(3y)-1199.47%
ROA(5y)-1754.68%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VRAX Yearly ROA, ROE, ROICVRAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

With a decent Gross Margin value of 39.58%, VRAX is doing good in the industry, outperforming 66.67% of the companies in the same industry.
VRAX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRAX Yearly Profit, Operating, Gross MarginsVRAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

6

2. Health

2.1 Basic Checks

VRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
VRAX has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, VRAX has a worse debt to assets ratio.
VRAX Yearly Shares OutstandingVRAX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
VRAX Yearly Total Debt VS Total AssetsVRAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

An Altman-Z score of 4.45 indicates that VRAX is not in any danger for bankruptcy at the moment.
VRAX has a better Altman-Z score (4.45) than 80.56% of its industry peers.
A Debt/Equity ratio of 0.06 indicates that VRAX is not too dependend on debt financing.
VRAX has a better Debt to Equity ratio (0.06) than 76.85% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 4.45
ROIC/WACCN/A
WACC9.1%
VRAX Yearly LT Debt VS Equity VS FCFVRAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

VRAX has a Current Ratio of 11.58. This indicates that VRAX is financially healthy and has no problem in meeting its short term obligations.
VRAX has a Current ratio of 11.58. This is amongst the best in the industry. VRAX outperforms 99.07% of its industry peers.
A Quick Ratio of 11.39 indicates that VRAX has no problem at all paying its short term obligations.
VRAX has a Quick ratio of 11.39. This is amongst the best in the industry. VRAX outperforms 99.07% of its industry peers.
Industry RankSector Rank
Current Ratio 11.58
Quick Ratio 11.39
VRAX Yearly Current Assets VS Current LiabilitesVRAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.26% over the past year.
VRAX shows a small growth in Revenue. In the last year, the Revenue has grown by 7.06%.
The Revenue has been growing by 9.23% on average over the past years. This is quite good.
EPS 1Y (TTM)34.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.81%
Revenue 1Y (TTM)7.06%
Revenue growth 3Y9.23%
Revenue growth 5YN/A
Sales Q2Q%-93.46%

3.2 Future

Based on estimates for the next years, VRAX will show a very strong growth in Earnings Per Share. The EPS will grow by 48.68% on average per year.
Based on estimates for the next years, VRAX will show a very strong growth in Revenue. The Revenue will grow by 210.44% on average per year.
EPS Next Y68.42%
EPS Next 2Y48.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year477.17%
Revenue Next 2Y210.44%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VRAX Yearly Revenue VS EstimatesVRAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
VRAX Yearly EPS VS EstimatesVRAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 0 -0.05 -0.1 -0.15

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

VRAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 33.33 indicates a quite expensive valuation of VRAX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of VRAX is on the same level as its industry peers.
VRAX is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.34, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 33.33
VRAX Price Earnings VS Forward Price EarningsVRAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRAX Per share dataVRAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

VRAX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
VRAX's earnings are expected to grow with 48.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.68%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VRAX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIRAX BIOLABS GROUP LTD

NASDAQ:VRAX (3/5/2025, 8:00:02 PM)

Premarket: 1.41 +0.05 (+3.68%)

1.36

-0.11 (-7.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)12-13 2022-12-13/bmo
Inst Owners6.72%
Inst Owner ChangeN/A
Ins Owners6.63%
Ins Owner ChangeN/A
Market Cap5.90M
AnalystsN/A
Price TargetN/A
Short Float %4.45%
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 33.33
P/S 69.52
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB 0.68
EV/EBITDA N/A
EPS(TTM)-2.6
EYN/A
EPS(NY)0.04
Fwd EY3%
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-1.05
OCFYN/A
SpS0.02
BVpS1.99
TBVpS1.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.69%
ROE -76.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.58%
FCFM N/A
ROA(3y)-1199.47%
ROA(5y)-1754.68%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 289.12%
Cap/Sales 829.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.58
Quick Ratio 11.39
Altman-Z 4.45
F-Score4
WACC9.1%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.81%
EPS Next Y68.42%
EPS Next 2Y48.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.06%
Revenue growth 3Y9.23%
Revenue growth 5YN/A
Sales Q2Q%-93.46%
Revenue Next Year477.17%
Revenue Next 2Y210.44%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-70.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.46%
OCF growth 3YN/A
OCF growth 5YN/A